Terms: = Lung cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
160 results:
1. Clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
Lee JE; Kim J; Hwang M; Kim YH; Chung MJ; Jeong WG; Jeong YJ
Korean J Radiol; 2024 May; 25(5):481-492. PubMed ID: 38627873
[TBL] [Abstract] [Full Text] [Related]
2. treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
3. The atr inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL; Sanseviero E; Karmokar A; Taylor D; Milo M; Michaloglou C; Hughes A; Mai M; King M; Solanki A; Magiera L; Miragaia R; Kar G; Standifer N; Surace M; Gill S; Peter A; Talbot S; Tohumeken S; Fryer H; Mostafa A; Mulgrew K; Lam C; Hoffmann S; Sutton D; Carnevalli L; Calero-Nieto FJ; Jones GN; Pierce AJ; Wilson Z; Campbell D; Nyoni L; Martins CP; Baker T; Serrano de Almeida G; Ramlaoui Z; Bidar A; Phillips B; Boland J; Iyer S; Barrett JC; Loembé AB; Fuchs SY; Duvvuri U; Lou PJ; Nance MA; Gomez Roca CA; Cadogan E; Critichlow SE; Fawell S; Cobbold M; Dean E; Valge-Archer V; Lau A; Gabrilovich DI; Barry ST
Nat Commun; 2024 Feb; 15(1):1700. PubMed ID: 38402224
[TBL] [Abstract] [Full Text] [Related]
4. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
5. Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic cancer.
Tummala T; Sevilla Uruchurtu AS; Cruz A; Huntington KE; George A; Liguori NR; Zhang L; Zhou L; Abbas AE; Azzoli CG; El-Deiry WS
Curr Oncol; 2023 Oct; 30(11):9611-9626. PubMed ID: 37999116
[TBL] [Abstract] [Full Text] [Related]
6. Copy number loss of KDM5D may be a predictive biomarker for atr inhibitor treatment in male patients with pulmonary squamous cell carcinoma.
Ura A; Hayashi T; Komura K; Hosoya M; Takamochi K; Sato E; Saito S; Wakai S; Handa T; Saito T; Kato S; Suzuki K; Yao T;
J Pathol Clin Res; 2024 Jan; 10(1):e350. PubMed ID: 37974379
[TBL] [Abstract] [Full Text] [Related]
7. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
[TBL] [Abstract] [Full Text] [Related]
8. Effects of Combined Therapeutic Targeting of AXL and atr on Pleural Mesothelioma Cells.
Hirai S; Yamada T; Katayama Y; Ishida M; Kawachi H; Matsui Y; Nakamura R; Morimoto K; Horinaka M; Sakai T; Sekido Y; Tokuda S; Takayama K
Mol Cancer Ther; 2024 Feb; 23(2):212-222. PubMed ID: 37802502
[TBL] [Abstract] [Full Text] [Related]
9. Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells.
Yadav KS; Raut HC; Nijhawan HP
Pharm Dev Technol; 2023 Oct; 28(8):755-767. PubMed ID: 37665569
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract] [Full Text] [Related]
11. 5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy.
Bjørnhart B; Mouritzen MT; Kristiansen C; Schytte T; Wedervang K; Pøhl M; Holmskov Hansen K
Acta Oncol; 2023 Aug; 62(8):861-870. PubMed ID: 37534770
[TBL] [Abstract] [Full Text] [Related]
12. atr inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW; Zhang Y; Elmeskini R; Zimmermann A; Fu H; Murai Y; Wangsa D; Kumar S; Takahashi N; Atkinson D; Saha LK; Lee CF; Elenbaas B; Desai P; Sebastian R; Sharma AK; Abel M; Schroeder B; Krishnamurthy M; Kumar R; Roper N; Aladjem M; Zenke FT; Ohler ZW; Pommier Y; Thomas A
EMBO Mol Med; 2023 Aug; 15(8):e17313. PubMed ID: 37491889
[TBL] [Abstract] [Full Text] [Related]
13. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through atr/CHK1 in NSCLC.
Zhao S; Yu N; Wang H; Wan Z; Diao C; Chen Y; Liu T; Yang Y; Gao F; Bai C; Cao K; Cai J
J Gene Med; 2023 Dec; 25(12):e3565. PubMed ID: 37460393
[TBL] [Abstract] [Full Text] [Related]
14. Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions.
Zhang C; Zhang C; Wang K; Wang H
J Transl Med; 2023 Jul; 21(1):468. PubMed ID: 37452395
[TBL] [Abstract] [Full Text] [Related]
15. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.
Yeo XH; Sundararajan V; Wu Z; Phua ZJC; Ho YY; Peh KLE; Chiu YC; Tan TZ; Kappei D; Ho YS; Tan DSP; Tam WL; Huang RY
Commun Biol; 2023 Jun; 6(1):660. PubMed ID: 37349576
[TBL] [Abstract] [Full Text] [Related]
16. Immunogenic cell death after combined treatment with radiation and atr inhibitors is dually regulated by apoptotic caspases.
Eek Mariampillai A; Hauge S; Kongsrud K; Syljuåsen RG
Front Immunol; 2023; 14():1138920. PubMed ID: 37346039
[TBL] [Abstract] [Full Text] [Related]
17. Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
Abel ML; Takahashi N; Peer C; Redon CE; Nichols S; Vilimas R; Lee MJ; Lee S; Shelat M; Kattappuram R; Sciuto L; Pinkiert D; Graham C; Butcher D; Karim B; Sharma AK; Malin J; Kumar R; Schultz CW; Goyal S; Del Rivero J; Krishnamurthy M; Upadhyay D; Schroeder B; Sissung T; Tyagi M; Kim J; Pommier Y; Aladjem M; Raffeld M; Figg WD; Trepel J; Xi L; Desai P; Thomas A
Clin Cancer Res; 2023 Sep; 29(18):3603-3611. PubMed ID: 37227187
[TBL] [Abstract] [Full Text] [Related]
18. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract] [Full Text] [Related]
19. LncRNA PCAT6 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma cell by targeting miR-545-3p.
Yang C; Huang H; Li Y; Zhuo T; Zhu L; Luo C; Wu Y; Qin S
Mol Biol Rep; 2023 Apr; 50(4):3557-3568. PubMed ID: 36787056
[TBL] [Abstract] [Full Text] [Related]
20. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and lung cancer.
Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X
Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125
[TBL] [Abstract] [Full Text] [Related]
[Next]
